FDA grants accelerated approval to pirtobrutinib for CLL/SLL — important new treatment option for patients fda.gov/drugs/resource…

Honored to be recognized by ⁦The Leukemia & Lymphoma Society⁩ for our work ⁦Dana-Farber⁩ over the last few years to develop better therapies for patients with #CLL! ⁦⁦Ross Levine⁩ lls.org/news/leukemia-…

It was great working with you Othman Al-Sawaf on the commentary — hopefully our perspective on this important topic is helpful to others.

I just committed to ride the Pan-Mass Challenge to support our research Dana-Farber. Click here to join me for #PMC2024! #OneInABillion secure.pmc.org/Ride #PMC2024 via @panmass

Exciting new tx option for pts with R/R CLL! FDA Approves Lisocabtagene Maraleucel for R/R CLL or SLL onclive.com/view/fda-appro… via @onclive

It was great to share the stage with you and learn from so many brilliant clinicians and scientists. Kudos to Charlie and the VJHemOnc team for the excellent organization of the mtg!

Well done Christine Ryan, MD and the Dana-Farber Lymphoma team!

Thank you Michael Hallek for the honor of inviting me to present the update of this important trial, and for the great friendship and collaboration between our groups in service of pts with CLL.

I highly encourage potential PhD students/postdocs to apply for a position to work with a brilliant and thoughtful PI Othman Al-Sawaf in an incredibly rich environment Uniklinik Köln

Hoping our pooled data analysis is helpful to better understand long-term efficacy of acalabrutinib in higher-risk CLL Jeff Sharman Toby Eyre onclive.com/view/acalabrut… via @onclive

Incorporating Maintenance Venetoclax After Venetoclax Plus Chemo for Richter’s Transformation in Transplant-Ineligible CLL dailynews.ascopubs.org/do/incorporati…

I highly encourage applying for this position in this dynamic group with an incredible PI/mentor Dana-Farber

Remember to join us on 12/06 at 11:00 AM PST for our #CLL live in-person & virtual symposium. Please tweet your questions in advance and follow PeerView for more #MedEd content! bit.ly/T2024-CLL #ASH2024 @CLLSociety

📢 📄 The abstract submission for the #18ICML is officially OPEN! Abstracts can be related to all aspects of the biology and treatment of #lymphoidneoplasms, including #CLL and #multiplemyeloma. More info: bit.ly/3ZBwOU3 #lymsm #lymphoma #myeloma

In a new study published in Journal of Clinical Oncology, Matthew Davids, MD, MMSc Dana-Farber shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk #CLL patients. The results were also presented this evening at #ASH24. Read more: bit.ly/3D3OCPP

Happy to share our new paper from ⁦⁦Dana-Farber⁩ on AVO for 1L CLL with high-risk genetics just published in ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/10.1200/JC…

Matthew S. Davids on Triplet Therapy of Acalabrutinib Venetoclax and Obinutuzumab Focus on TP53 Aberrant CLL - The ASCO Post ascopost.com/videos/2024-as…

Please add this great VJHemOnc event to your Jan calendar now so you don't miss it: Post-ASH 2024 CLL highlights webinar us06web.zoom.us/webinar/regist…

Thanks for having me on the podcast chadi nabhan MD, MBA, FACP, it was a lot of fun! Dana-Farber Pan-Mass Challenge CLL Society Inc.

I just committed to ride my 15th consecutive Pan-Mass Challenge bike ride on Aug 2/3 to support our CLL and lymphoma research Dana-Farber. Click here to support my ride! #CloserByTheMile donate.pmc.org/MD0305 #PMC2025 via @panmass